Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ACP3 | P15309 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22321990 | 0.90 | PPARG (0.52) | PPARGPPARAACP3KDM4EALDH1A1 | |
| SCHEMBL20703817 | 0.86 | KLK8 (0.45) | PPARGPPARAL3MBTL1MAPK14MEN1 | |
| SCHEMBL1832383 | 0.83 | ACP3 (0.60) | ACP3NR4A2NPSR1MEN1LMNA | |
| SCHEMBL29427108 | 0.83 | ACP3 (0.60) | ACP3NR4A2NPSR1MEN1LMNA | |
| SCHEMBL17923878 | 0.82 | KLK8 (0.50) | L3MBTL1NPSR1MEN1KMT2A | |
| SCHEMBL20710779 | 0.82 | LMNA (0.56) | L3MBTL1KDM4EALDH1A1NPSR1MEN1 | |
| SCHEMBL20710757 | 0.82 | L3MBTL1 (0.49) | PPARGPPARAL3MBTL1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL8896648 | 0.81 | KLK8 (0.49) | L3MBTL1NPSR1MEN1KMT2A | |
| SCHEMBL22321991 | 0.79 | ACP3 (0.56) | PPARGPPARAACP3KDM4EALDH1A1 | |
| SCHEMBL8957011 | 0.78 | ACP3 (0.55) | ACP3NPSR1MEN1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927135-B2 | Metal-free direct arylation of dialkyl phosphonates for the synthesis of mixed alkyl aryl phosphonates | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200255461-A1 | METAL-FREE DIRECT ARYLATION OF DIALKYL PHOSPHONATES FOR THE SYNTHESIS OF MIXED ALKYL ARYL PHOSPHONATES | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2020-08-13 | — | — | US | disclosed |
| WO-2019028391-A1 | METAL-FREE DIRECT ARYLATION OF DIALKYL PHOSPHONATES FOR THE SYNTHESIS OF MIXED ALKYL ARYL PHOSPHONATES | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255461-A1 | METAL-FREE DIRECT ARYLATION OF DIALKYL PHOSPHONATES FOR THE SYNTHESIS OF MIXED ALKYL ARYL PHOSPHONATES | SLC35B2, PPIP5K2, PPA1 | PPARG 892/4885PPARA 511/4885L3MBTL1 4127/4885 |
| US-10927135-B2 | Metal-free direct arylation of dialkyl phosphonates for the synthesis of mixed alkyl aryl phosphonates | SLC35B2, PPIP5K2, PPA1 | PPARG 892/4885PPARA 511/4885L3MBTL1 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.